Caladrius Biosciences

From Wikipedia, the free encyclopedia
Caladrius Biosciences
TypePublic
Nasdaq: CLBS
Russell Microcap Index component
IndustryBiopharmaceuticals
HeadquartersBasking Ridge, New Jersey[1],
United States
Key people
David J. Mazzo
(CEO)
Websitecaladrius.com

Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]

Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.[3]

Cardiovascular disease[]

In 2012 it started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for acute myocardial infarction.[5] Initial results included a statistically significant mortality benefit.[6]

References[]

  1. ^ Editorial, Reuters. "CLBS.PH - Caladrius Biosciences Inc Profile | Reuters". www.reuters.comundefined.
  2. ^ NeoStem CEO Discusses Adult Stem Cell Therapies, May 14, 2012. Bloomberg Television. 3m35s video. Accessed September 2015.
  3. ^ Jump up to: a b "Caladrius Biosciences - Consensus Indicates Potential 316.7% Upside - DirectorsTalk Interviews". Retrieved 2021-05-03.
  4. ^ EDGAR Search Results – Neostem, EDGAR
  5. ^ NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)
  6. ^ Stem Cell Research Reveals Promising Data for Heart Attack Patients. Feb 2015
Retrieved from ""